NasdaqGM - Delayed Quote USD

Immuneering Corporation (IMRX)

2.1300
+0.0800
+(3.90%)
At close: June 6 at 4:00:01 PM EDT
2.2889
+0.16
+(7.46%)
After hours: June 6 at 7:54:14 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
0
316.9520
2,079.9610
Cost of Revenue
--
--
0
158.1220
1,153.0730
Gross Profit
--
--
0
158.8300
926.8880
Operating Expense
64,230.9340
64,071.6550
58,413.2850
51,904.1690
34,812.9590
Operating Income
-64,230.9340
-64,071.6550
-58,413.2850
-51,745.3390
-33,886.0710
Net Non Operating Interest Income Expense
2,226.9360
2,593.3000
3,606.9960
1,014.4560
169.8990
Other Income Expense
--
441.4930
1,334.2690
216.8440
-127.0630
Pretax Income
-61,775.5420
-61,036.8620
-53,472.0200
-50,514.0390
-33,843.2350
Tax Provision
--
--
--
0
-307.4850
Net Income Common Stockholders
-61,774.9110
-61,036.6080
-53,471.6220
-50,513.5680
-33,535.7480
Diluted NI Available to Com Stockholders
-61,774.9110
-61,036.6080
-53,471.6220
-50,513.5680
-33,535.7480
Basic EPS
-1.97
-2.04
-1.88
-1.91
-2.46
Diluted EPS
-1.97
-2.04
-1.88
-1.91
-2.46
Basic Average Shares
31,521.3890
29,981.5650
28,416.5580
26,386.8640
13,612.6770
Diluted Average Shares
31,521.3890
29,981.5650
28,416.5580
26,386.8640
13,612.6770
Total Operating Income as Reported
-64,230.3030
-64,071.4010
-58,412.8870
-51,744.8680
-33,886.0690
Rent Expense Supplemental
--
--
--
--
108
Total Expenses
64,230.9340
64,071.6550
58,413.2850
52,062.2910
35,966.0320
Net Income from Continuing & Discontinued Operation
-61,774.9110
-61,036.6080
-53,471.6220
-50,513.5680
-33,535.7480
Normalized Income
-61,774.9110
-61,036.6080
-53,471.6220
-50,513.5680
-33,535.7480
Interest Income
2,226.9360
2,593.3000
3,606.9960
1,014.4560
169.8990
Net Interest Income
2,226.9360
2,593.3000
3,606.9960
1,014.4560
169.8990
EBIT
-64,230.9340
-64,071.6550
-58,413.2850
-51,745.3390
-33,886.0710
EBITDA
-63,850.8080
-63,686.5810
-58,061.2020
-51,468.0870
-33,726.9990
Reconciled Cost of Revenue
--
--
0
158.1220
994.0010
Reconciled Depreciation
380.1260
385.0740
352.0830
277.2520
159.0720
Net Income from Continuing Operation Net Minority Interest
-61,774.9110
-61,036.6080
-53,471.6220
-50,513.5680
-33,535.7480
Normalized EBITDA
-63,850.8080
-63,686.5810
-58,061.2020
-51,468.0870
-33,726.9990
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 7/30/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

JSPR Jasper Therapeutics, Inc.
6.01
+5.44%
 
XLO Xilio Therapeutics, Inc.
0.7000
+3.20%
 
TRVI Trevi Therapeutics, Inc.
7.06
+4.75%
 
VTYX Ventyx Biosciences, Inc.
2.4600
+9.33%
 
LXEO Lexeo Therapeutics, Inc.
3.8800
+18.65%
 
CGEM Cullinan Therapeutics, Inc.
9.08
+3.89%
 
KURA Kura Oncology, Inc.
6.73
+2.44%
 
CGTX Cognition Therapeutics, Inc.
0.2953
+1.79%
 
ORIC ORIC Pharmaceuticals, Inc.
9.32
+1.75%
 
IMTX Immatics N.V.
5.97
+3.29%